Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Janux Therapeutics Inc (NQ: JANX ) 46.98 +2.34 (+5.24%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Janux Therapeutics Inc < Previous 1 2 3 4 5 Next > Analyst Expectations For Janux Therapeutics's Future August 09, 2024 Via Benzinga JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 07, 2024 JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights August 07, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics Announces Updates to Board of Directors July 22, 2024 From Janux Therapeutics Via Business Wire The Latest Analyst Ratings For Janux Therapeutics May 30, 2024 Via Benzinga Analyst Ratings For Janux Therapeutics May 13, 2024 Via Benzinga A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts April 16, 2024 Via Benzinga GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing July 18, 2024 GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. Via Benzinga UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday July 16, 2024 Via Benzinga 3 Biotech Stocks That Can Gain Exponentially By Leveraging AI July 02, 2024 Although fraught with risk, these biotech exposures bring enormous upside potential. Via Talk Markets Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday May 31, 2024 Via Benzinga Why Janux Therapeutics Stock Is Crushing It This Week April 12, 2024 Janux's silence about a potential acquisition deal could be golden. Via The Motley Fool Forecasting The Future: 4 Analyst Projections For Janux Therapeutics March 20, 2024 Via Benzinga JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 07, 2024 From Janux Therapeutics Via Business Wire Take the Money and Run: 3 Overbought Stocks to Sell ASAP April 17, 2024 Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming. Via InvestorPlace These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? April 16, 2024 These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? Via InvestorPlace Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 11, 2024 Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Via Benzinga Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? April 11, 2024 Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The... Via Benzinga Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday April 11, 2024 U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Via Benzinga Topics Stocks Exposures US Equities Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options April 11, 2024 Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. Via Investor's Business Daily Why Janux Therapeutics Stock Soared as the Market Sagged Today April 10, 2024 One of the hotter biotech companies on the scene might be changing owners before long. Via The Motley Fool 10 Health Care Stocks Whale Activity In Today's Session April 04, 2024 Via Benzinga Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst March 20, 2024 Cantor Fitzgerald's coverage on Janux Therapeutics and its TRACTr/TRACir platform targeting diverse tumor antigens and cancer types. Analysts anticipate substantial growth potential driven by JANX007,... Via Benzinga JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 15, 2024 JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. Via InvestorPlace 2 Stocks That Have More Than Tripled This Year: Are They Buys? March 15, 2024 Don't jump on the bandwaggon too quickly. Via The Motley Fool B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know March 13, 2024 Via Benzinga Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 12, 2024 Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Via Benzinga Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights March 08, 2024 From Janux Therapeutics Via Business Wire 5 Stocks That More Than Doubled In February March 03, 2024 U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade. Meanwhile, the Dow Via Talk Markets Topics Stocks Exposures US Equities < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.